Julie J. Miller, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glioma | 25 | 2024 | 3395 | 4.520 |
Why?
|
Isocitrate Dehydrogenase | 23 | 2024 | 916 | 3.510 |
Why?
|
Brain Neoplasms | 20 | 2024 | 8892 | 1.760 |
Why?
|
Central Nervous System Neoplasms | 3 | 2023 | 905 | 1.030 |
Why?
|
Mutation | 22 | 2024 | 29705 | 0.990 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2024 | 70 | 0.950 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2024 | 343 | 0.770 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2024 | 694 | 0.750 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2024 | 552 | 0.720 |
Why?
|
Aminopyridines | 1 | 2024 | 560 | 0.720 |
Why?
|
Astrocytoma | 2 | 2024 | 778 | 0.670 |
Why?
|
Benzimidazoles | 1 | 2024 | 854 | 0.650 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2024 | 3553 | 0.620 |
Why?
|
Sirtuins | 1 | 2021 | 318 | 0.610 |
Why?
|
Arginine | 1 | 2021 | 927 | 0.590 |
Why?
|
Pyridines | 2 | 2024 | 2861 | 0.510 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2022 | 1373 | 0.470 |
Why?
|
Drugs, Investigational | 1 | 2016 | 213 | 0.470 |
Why?
|
Behcet Syndrome | 1 | 2014 | 86 | 0.460 |
Why?
|
Piperazines | 1 | 2024 | 2486 | 0.450 |
Why?
|
Glioblastoma | 4 | 2024 | 3471 | 0.370 |
Why?
|
F-Box Proteins | 3 | 2007 | 202 | 0.370 |
Why?
|
Central Nervous System Diseases | 1 | 2014 | 519 | 0.350 |
Why?
|
Oligodendroglioma | 2 | 2024 | 283 | 0.350 |
Why?
|
Cell Proliferation | 3 | 2024 | 10358 | 0.350 |
Why?
|
Ubiquitin-Protein Ligase Complexes | 3 | 2007 | 168 | 0.340 |
Why?
|
Cell Line, Tumor | 7 | 2024 | 16736 | 0.330 |
Why?
|
Cancer Vaccines | 1 | 2016 | 1048 | 0.320 |
Why?
|
Protein Kinase Inhibitors | 2 | 2024 | 5594 | 0.310 |
Why?
|
Methylation | 2 | 2021 | 1075 | 0.310 |
Why?
|
NAD | 3 | 2021 | 594 | 0.300 |
Why?
|
Autoimmunity | 1 | 2014 | 1344 | 0.270 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13553 | 0.270 |
Why?
|
Cell Cycle Proteins | 5 | 2018 | 3435 | 0.250 |
Why?
|
Enzyme Inhibitors | 3 | 2023 | 3703 | 0.250 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2020 | 617 | 0.240 |
Why?
|
Gene Deletion | 2 | 2024 | 2665 | 0.230 |
Why?
|
Diamines | 1 | 2024 | 58 | 0.230 |
Why?
|
DNA Modification Methylases | 2 | 2020 | 205 | 0.210 |
Why?
|
Humans | 44 | 2024 | 752341 | 0.200 |
Why?
|
Immunotherapy | 2 | 2022 | 4601 | 0.200 |
Why?
|
DNA Repair Enzymes | 2 | 2020 | 344 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9207 | 0.180 |
Why?
|
Hexokinase | 1 | 2020 | 125 | 0.180 |
Why?
|
Glycoside Hydrolases | 1 | 2020 | 133 | 0.180 |
Why?
|
Sirtuin 1 | 1 | 2021 | 246 | 0.170 |
Why?
|
Homozygote | 1 | 2024 | 1784 | 0.170 |
Why?
|
Transcription Factor RelA | 1 | 2020 | 251 | 0.170 |
Why?
|
Tretinoin | 1 | 2022 | 522 | 0.160 |
Why?
|
Cyanides | 1 | 2018 | 82 | 0.150 |
Why?
|
Promoter Regions, Genetic | 2 | 2020 | 5782 | 0.150 |
Why?
|
Inflammation | 2 | 2014 | 10690 | 0.150 |
Why?
|
Guanidines | 1 | 2018 | 191 | 0.150 |
Why?
|
World Health Organization | 1 | 2023 | 1294 | 0.140 |
Why?
|
Dystrophin | 1 | 2018 | 286 | 0.140 |
Why?
|
Epidural Neoplasms | 1 | 2016 | 23 | 0.140 |
Why?
|
Telomerase | 2 | 2018 | 740 | 0.140 |
Why?
|
Molecular Targeted Therapy | 2 | 2018 | 2782 | 0.130 |
Why?
|
DNA Mismatch Repair | 1 | 2018 | 427 | 0.130 |
Why?
|
Emergencies | 1 | 2022 | 1176 | 0.130 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 887 | 0.120 |
Why?
|
Dacarbazine | 1 | 2017 | 560 | 0.120 |
Why?
|
Tumor Suppressor Proteins | 3 | 2020 | 2796 | 0.120 |
Why?
|
Radiographic Image Enhancement | 1 | 2018 | 879 | 0.110 |
Why?
|
Histones | 1 | 2024 | 2566 | 0.110 |
Why?
|
Mice, SCID | 4 | 2020 | 2617 | 0.110 |
Why?
|
Consensus | 1 | 2023 | 3034 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2018 | 990 | 0.110 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2018 | 5163 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 2978 | 0.100 |
Why?
|
Drug Design | 1 | 2016 | 1058 | 0.100 |
Why?
|
Lymphoma | 1 | 2020 | 1887 | 0.100 |
Why?
|
Nervous System Diseases | 1 | 2022 | 1624 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2440 | 0.090 |
Why?
|
Blood-Brain Barrier | 1 | 2016 | 1014 | 0.090 |
Why?
|
Animals | 13 | 2024 | 166802 | 0.090 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 2064 | 0.090 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 8538 | 0.090 |
Why?
|
Stress, Physiological | 1 | 2017 | 1392 | 0.090 |
Why?
|
Kidney Diseases, Cystic | 1 | 2011 | 182 | 0.090 |
Why?
|
Mice | 9 | 2024 | 80543 | 0.080 |
Why?
|
Meningioma | 1 | 2018 | 1209 | 0.080 |
Why?
|
Meningeal Neoplasms | 1 | 2018 | 1232 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2018 | 2868 | 0.080 |
Why?
|
Radiation Injuries | 1 | 2016 | 1180 | 0.080 |
Why?
|
DNA | 1 | 2022 | 7215 | 0.080 |
Why?
|
S-Phase Kinase-Associated Proteins | 2 | 2005 | 90 | 0.080 |
Why?
|
Diagnostic Imaging | 1 | 2022 | 3502 | 0.070 |
Why?
|
Maturation-Promoting Factor | 1 | 2007 | 26 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-mos | 1 | 2007 | 17 | 0.070 |
Why?
|
Nuclear Matrix-Associated Proteins | 1 | 2007 | 39 | 0.070 |
Why?
|
Anaphase | 1 | 2007 | 117 | 0.070 |
Why?
|
Signal Transduction | 5 | 2020 | 23233 | 0.070 |
Why?
|
Cerebral Amyloid Angiopathy | 1 | 2014 | 879 | 0.070 |
Why?
|
Antigens, Nuclear | 1 | 2007 | 185 | 0.070 |
Why?
|
Cell Differentiation | 1 | 2024 | 11422 | 0.070 |
Why?
|
Amino Acid Motifs | 2 | 2006 | 930 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 3599 | 0.070 |
Why?
|
Young Adult | 4 | 2020 | 57629 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 1 | 2018 | 4474 | 0.070 |
Why?
|
Interphase | 1 | 2006 | 229 | 0.070 |
Why?
|
Cytokines | 1 | 2021 | 7235 | 0.070 |
Why?
|
Cerebrovascular Circulation | 1 | 2016 | 2708 | 0.060 |
Why?
|
Disease Progression | 2 | 2019 | 13402 | 0.060 |
Why?
|
Cullin Proteins | 2 | 2005 | 178 | 0.060 |
Why?
|
Binding, Competitive | 1 | 2006 | 1137 | 0.060 |
Why?
|
Survival Rate | 1 | 2019 | 12746 | 0.060 |
Why?
|
Adult | 6 | 2024 | 216913 | 0.060 |
Why?
|
Prognosis | 3 | 2022 | 29327 | 0.060 |
Why?
|
Xenopus Proteins | 1 | 2007 | 432 | 0.060 |
Why?
|
Genotype | 1 | 2018 | 12869 | 0.060 |
Why?
|
HeLa Cells | 2 | 2007 | 3086 | 0.060 |
Why?
|
Cloning, Molecular | 1 | 2009 | 4166 | 0.060 |
Why?
|
Migraine Disorders | 1 | 2016 | 1665 | 0.050 |
Why?
|
Conserved Sequence | 1 | 2006 | 1165 | 0.050 |
Why?
|
Up-Regulation | 2 | 2024 | 4115 | 0.050 |
Why?
|
Substrate Specificity | 1 | 2006 | 1785 | 0.050 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2005 | 656 | 0.050 |
Why?
|
Peptide Synthases | 1 | 2002 | 80 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2019 | 58300 | 0.050 |
Why?
|
Cadherins | 1 | 2006 | 904 | 0.050 |
Why?
|
Protein Binding | 4 | 2007 | 9273 | 0.050 |
Why?
|
Receptor, Notch1 | 1 | 2024 | 499 | 0.050 |
Why?
|
Ligases | 1 | 2002 | 331 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2016 | 7995 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2024 | 3755 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2024 | 815 | 0.040 |
Why?
|
Viral Matrix Proteins | 1 | 2020 | 196 | 0.040 |
Why?
|
Brain | 2 | 2023 | 26655 | 0.040 |
Why?
|
Multiprotein Complexes | 1 | 2005 | 1114 | 0.040 |
Why?
|
Sex Chromatin | 1 | 2018 | 19 | 0.040 |
Why?
|
Pteridines | 1 | 2018 | 43 | 0.040 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2005 | 1873 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 4 | 2018 | 35916 | 0.040 |
Why?
|
Aged | 6 | 2024 | 166562 | 0.040 |
Why?
|
Middle Aged | 7 | 2024 | 217019 | 0.040 |
Why?
|
Female | 11 | 2024 | 386053 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39079 | 0.040 |
Why?
|
Cell Nucleus | 1 | 2006 | 2904 | 0.040 |
Why?
|
Nicotinamide Phosphoribosyltransferase | 1 | 2017 | 83 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2024 | 14586 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2018 | 699 | 0.030 |
Why?
|
Glycolysis | 1 | 2020 | 825 | 0.030 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2020 | 579 | 0.030 |
Why?
|
Astrocytes | 1 | 2024 | 1318 | 0.030 |
Why?
|
Antigens, CD | 1 | 2006 | 3908 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2024 | 8422 | 0.030 |
Why?
|
Proteomics | 1 | 2009 | 3750 | 0.030 |
Why?
|
Acrylamides | 1 | 2017 | 256 | 0.030 |
Why?
|
Cell Lineage | 1 | 2024 | 2511 | 0.030 |
Why?
|
Cell Line | 1 | 2009 | 15633 | 0.030 |
Why?
|
Membrane Proteins | 1 | 2011 | 7808 | 0.030 |
Why?
|
Proteins | 1 | 2009 | 6015 | 0.030 |
Why?
|
Male | 7 | 2024 | 354881 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2019 | 79127 | 0.030 |
Why?
|
Stroke | 1 | 2016 | 9879 | 0.030 |
Why?
|
Mitosis | 1 | 2018 | 1192 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2318 | 0.030 |
Why?
|
Protein Structure, Quaternary | 2 | 2005 | 427 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 3468 | 0.030 |
Why?
|
Random Allocation | 1 | 2017 | 2387 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6137 | 0.030 |
Why?
|
Mice, Nude | 1 | 2018 | 3582 | 0.030 |
Why?
|
Gene Silencing | 1 | 2018 | 1514 | 0.020 |
Why?
|
NF-kappa B | 1 | 2020 | 2471 | 0.020 |
Why?
|
Down-Regulation | 1 | 2018 | 2910 | 0.020 |
Why?
|
Acute Disease | 1 | 2022 | 7211 | 0.020 |
Why?
|
Ciliary Motility Disorders | 1 | 2011 | 51 | 0.020 |
Why?
|
Polycystic Kidney Diseases | 1 | 2011 | 133 | 0.020 |
Why?
|
Encephalocele | 1 | 2011 | 135 | 0.020 |
Why?
|
Centrosome | 1 | 2011 | 206 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2011 | 672 | 0.020 |
Why?
|
Neoplasms | 2 | 2016 | 21808 | 0.020 |
Why?
|
Crystallography, X-Ray | 2 | 2005 | 1967 | 0.020 |
Why?
|
Piperidines | 1 | 2017 | 1645 | 0.020 |
Why?
|
DNA Damage | 1 | 2018 | 2407 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2895 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6501 | 0.020 |
Why?
|
Retinitis Pigmentosa | 1 | 2011 | 394 | 0.020 |
Why?
|
Cyclin B | 1 | 2007 | 104 | 0.020 |
Why?
|
Cilia | 1 | 2011 | 487 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2213 | 0.020 |
Why?
|
Dyneins | 1 | 2007 | 125 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2020 | 3029 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 21841 | 0.020 |
Why?
|
CDC2 Protein Kinase | 1 | 2007 | 212 | 0.020 |
Why?
|
Hedgehog Proteins | 1 | 2011 | 769 | 0.020 |
Why?
|
HCT116 Cells | 1 | 2007 | 402 | 0.020 |
Why?
|
Cohort Studies | 2 | 2018 | 40984 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2024 | 17958 | 0.020 |
Why?
|
Chromosomes, Human | 1 | 2007 | 445 | 0.020 |
Why?
|
Feedback, Physiological | 1 | 2007 | 474 | 0.020 |
Why?
|
Mammals | 1 | 2009 | 1127 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2018 | 12738 | 0.010 |
Why?
|
Amino Acid Sequence | 2 | 2007 | 13410 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2022 | 64245 | 0.010 |
Why?
|
Protein Structure, Secondary | 1 | 2005 | 1226 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2022 | 7734 | 0.010 |
Why?
|
Oocytes | 1 | 2007 | 1167 | 0.010 |
Why?
|
Microtubule-Associated Proteins | 1 | 2007 | 1078 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2007 | 17591 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25535 | 0.010 |
Why?
|
Ubiquitin-Conjugating Enzymes | 1 | 2002 | 195 | 0.010 |
Why?
|
SKP Cullin F-Box Protein Ligases | 1 | 2002 | 174 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2002 | 319 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2018 | 9551 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2009 | 3724 | 0.010 |
Why?
|
Ubiquitins | 1 | 2002 | 372 | 0.010 |
Why?
|
Adolescent | 2 | 2018 | 86765 | 0.010 |
Why?
|
Zebrafish | 1 | 2011 | 2995 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 2002 | 1433 | 0.010 |
Why?
|
Cell Division | 1 | 2007 | 4445 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2011 | 4412 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2002 | 2750 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2002 | 2175 | 0.010 |
Why?
|
Cell Cycle | 1 | 2005 | 2928 | 0.010 |
Why?
|
Ubiquitin | 1 | 2002 | 833 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 2002 | 3078 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2002 | 3786 | 0.010 |
Why?
|
Phosphorylation | 1 | 2005 | 8315 | 0.010 |
Why?
|
Binding Sites | 1 | 2002 | 6028 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2005 | 4932 | 0.010 |
Why?
|
Models, Molecular | 1 | 2002 | 5385 | 0.010 |
Why?
|